These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25771436)

  • 1. Global optimal vaccination in the SIR model: properties of the value function and application to cost-effectiveness analysis.
    Laguzet L; Turinici G
    Math Biosci; 2015 May; 263():180-97. PubMed ID: 25771436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feedback control problem of an SIR epidemic model based on the Hamilton-Jacobi-Bellman equation.
    Hwang YG; Kwon HD; Lee J
    Math Biosci Eng; 2020 Jan; 17(3):2284-2301. PubMed ID: 32233535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of vaccination programs: the impact of herd-immunity.
    Brisson M; Edmunds WJ
    Med Decis Making; 2003; 23(1):76-82. PubMed ID: 12583457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Threshold dynamics and optimal control on an age-structured SIRS epidemic model with vaccination.
    Ma H; Zhang Q
    Math Biosci Eng; 2021 Oct; 18(6):9474-9495. PubMed ID: 34814354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal vaccination policies for an SIR model with limited resources.
    Zhou Y; Yang K; Zhou K; Liang Y
    Acta Biotheor; 2014 Jun; 62(2):171-81. PubMed ID: 24723249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal control of vaccination dynamics during an influenza epidemic.
    Jaberi-Douraki M; Moghadas SM
    Math Biosci Eng; 2014 Oct; 11(5):1045-63. PubMed ID: 25347806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal vaccination in a SIRS epidemic model.
    Federico S; Ferrari G; Torrente ML
    Econ Theory; 2022 Dec; ():1-26. PubMed ID: 36573250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential impact of reactive vaccination in controlling cholera outbreaks: an exploratory analysis using a Zimbabwean experience.
    Kim SY; Choi Y; Mason PR; Rusakaniko S; Goldie SJ
    S Afr Med J; 2011 Sep; 101(9):659-64. PubMed ID: 21920160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness.
    Bauch CT; Anonychuk AM; Van Effelterre T; Pham BZ; Merid MF
    Med Decis Making; 2009; 29(5):557-69. PubMed ID: 19605882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Least squares solutions of the HJB equation with neural network value-function approximators.
    Tassa Y; Erez T
    IEEE Trans Neural Netw; 2007 Jul; 18(4):1031-41. PubMed ID: 17668659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of population heterogeneity on herd immunity and on vaccination decision making process.
    Bai F
    J Theor Biol; 2021 Oct; 526():110795. PubMed ID: 34102199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulse vaccination strategy in the SIR epidemic model.
    Shulgin B; Stone L; Agur Z
    Bull Math Biol; 1998 Nov; 60(6):1123-48. PubMed ID: 9866452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling infectious diseases with herd immunity in a randomly mixed population.
    Law KB; M Peariasamy K; Mohd Ibrahim H; Abdullah NH
    Sci Rep; 2021 Oct; 11(1):20574. PubMed ID: 34663839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability analysis and optimal vaccination of an SIR epidemic model.
    Zaman G; Han Kang Y; Jung IH
    Biosystems; 2008 Sep; 93(3):240-9. PubMed ID: 18584947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.
    Atkins KE; Shim E; Carroll S; Quilici S; Galvani AP
    Vaccine; 2012 Nov; 30(48):6766-76. PubMed ID: 23000223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.